Accuracy of Scoring Systems for Risk Assessment in Neonatal Intensive Care Unit

March 12, 2023 updated by: Rehab Zain Elabdeen Abdelfattah, Sohag University

Accuracy of Scoring Systems for Risk Assessment in Neonatal Intensive Care Unit at Sohag University Hospital

Early detection of neonates with higher risk of death is quite important for paying more attention to these cases, timely referral to tertiary neonatal intensive care unit (NICU), and provision of meticulous critical care, which ultimately may improve outcomes. Several scoring systems have recently been developed for assessment of the intensity of illness and prognosticate the risk of not only neonatal mortality but also short- and long-term morbidities. The accuracy of these scoring systems has been investigated in several NICUs from different countries, such as USA, UK, Canada, Brazil, India, and Iran. Previous Egyptian studies have investigated the accuracy of Clinical Risk Index for Babies II (CRIB II), Score for Neonatal Acute Physiology II (SNAP-II) and its Perinatal Extension II (SNAPPE-II). However, the accuracy of Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar (STOPS), Modified Sick neonatal Score (MSNS), and neonatal sequential organ failure assessment (nSOFA) has not been investigated in Egyptian NICUs. Therefore, more studies are required to investigate the utility and accuracy of neonatal risk assessment scores in Egyptian NICUs.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Sohag, Egypt, 82524
        • Recruiting
        • Neonatal Intensive Care Units at Sohag University Hospitals
        • Contact:
        • Principal Investigator:
          • Elsayed Abdelkreem, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 4 weeks (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Neonates admitted to NICUs at Sohag University Hospitals during the study duration

Description

Inclusion Criteria:

  • Admission within 24 hours after birth.
  • Length of hospital stay at the first admission to NICU ≥12 hours

Exclusion Criteria:

  • Major congenital anomalies.
  • Discharge against medical advice
  • Transportation to other places.
  • Missing data on items of scoring systems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Study participants
Neonates admitted to NICU and fulfilling eligibility criteria
Calculate Clinical Risk Index for Babies II score
Calculate Score for Neonatal Acute Physiology II
Calculate Score for Neonatal Acute Physiology Perinatal Extension II
Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
Calculate Modified Sick neonatal Score
Calculate neonatal sequential organ failure assessment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival at discharge
Time Frame: One year
Proportion of neonates discharged alive from NICU
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of hospital stay
Time Frame: One year
Length of stay in NICU
One year
Need for CPAP
Time Frame: One year
Proportion of neonates connected to continuous positive airway pressure
One year
Need for invasive ventilation
Time Frame: One year
Proportion of neonates requiring invasive ventilation
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 12, 2023

Primary Completion (Anticipated)

April 1, 2024

Study Completion (Anticipated)

April 10, 2024

Study Registration Dates

First Submitted

February 28, 2023

First Submitted That Met QC Criteria

February 28, 2023

First Posted (Actual)

March 10, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2023

Last Update Submitted That Met QC Criteria

March 12, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • Soh-Med-23-03-10MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Unidentified individual participant data will be available from the principal investigator upon a reasonable request

IPD Sharing Time Frame

After publication and for three years

IPD Sharing Access Criteria

Available from the principal investigator upon a reasonable request

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neonatal Death

Clinical Trials on CRIB II

3
Subscribe